Important Announcement


ChemIDplus is moving to PubChem in December 2022.
Please see the NLM Technical Bulletin article for more information.

Skip Navigation
ChemIDplus LiteBrowseAdvanced

Substance Name: Ublituximab [USAN:INN]
RN: 1174014-05-1


  • NCI: A chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ublituximab specifically binds to the B cell-specific cell surface antigen CD20, thereby potentially inducing a B cell-directed complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B cells, leading to B cell apoptosis. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development and is often overexpressed in B-cell malignancies. Ublituximab has a specific glycosylation profile, with a low fucose content, that may enhance its ADCC response against malignant B cells. (NCI Thesaurus)
  • Targets a unique epitope on the B-lymphocyte CD20 antigen.

Molecular Formula

  • C6418-H9866-N1702-O2006-S48

Classification Code

  • Treatment of Cancer, Autoimmune Disorders
* denotes mobile formatted website

Links to Resources

NLM Resources (File Locators)

Other Resources (Internet Locators)

Names and Synonyms

Name of Substance

  • Ublituximab
  • Ublituximab [USAN:INN]


  • Immunoglobulin G1, anti-(human cd20 (antigen)) (human-mouse monoclonal gamma1-chain), disulfide with human-mouse monoclonal kappa-chain, dimer
  • LFB-R603
  • TG-1101
  • Ublituximab

Registry Numbers

CAS Registry Number

  • 1174014-05-1


  • U59UGK3IPC

System Generated Number

  • 1174014051